



SNAPSHOT OF STEM CELL AND REGENERATIVE MEDICINE COMPANIES IN AUSTRALIA

10th Edition
2024

INDEX


Foreword	4
Was the decline in venture financing partially fuelled by a breakdown in the Triple Helix Innovation Model?	7
Companies	
Australian-based Stem Cell and Regenerative Medicine Companies	
Cynata	12
Cryosite	14
Mesoblast	15
Clinical Trials in Australia	17
Directory of Stem Cell and Regenerative Medicine Companies	19

ABOUT THIS SNAPSHOT

This is the tenth version of the snapshot, which highlights key regenerative medicine companies, largely compiled from information that was publicly available. The information contained within this Snapshot is up-to-date and relevant as of 23rd October 2024. The publication was launched online, in conjunction with the Centre for Commercialization of Regenerative Medicine Australia at the NSW Stem Cell Network's 34th workshop; Building Cell Therapy Careers and Companies on October 23rd, 2024 at Christie Conference Spaces, North Sydney.

Disclaimer:

The information contained in the Snapshot of Stem Cell and Regenerative Medicine Companies in Australia: October 2024 is intended solely for general information. This publication must not be relied upon as a substitute for medical, investment or other professional advice. You are encouraged to speak with the relevant contacts provided in the Snapshot for further information. This Snapshot should not be read as reflecting the policies of the NSW Stem Cell Network, its Executive, officers or members. Nor does the Snapshot represent an endorsement of the processes, procedures and technologies described therein. The NSW Stem Cell Network does not accept any liability arising in any way from information contained in this publication, including by reason of negligence for errors or omissions in the information. Only companies that have agreed to be published in the Snapshot were included and, any liability for their content resides with them.



FOREWORD

A simple search will reveal that in the first half of 2024, there have been several rejections by the FDA due to manufacturing concerns. These rejections include Melinta Therapeutics & Venatorx Pharmaceutical (combination antibiotic), Rocket Pharmaceutical (gene therapy), Novo Nordisk (insulin), Abeona Therapeutics (cell therapy), AbbVie (prodrug), Daiichi Sankyo & Merck (antibody-drug conjugate) and Astellas (monoclonal antibody). These novel therapies target debilitating diseases such as Parkinson's, small cell lung cancer and gastric cancer, which would no doubt bring profound benefits to patients. Hence manufacturing is one of the top concerns voiced by investors in the cell and gene therapy sector.

The importance of manufacturing can be appreciated from many perspectives. Fundamentally, we know that the ability to manufacture a drug or therapy consistently and repeatedly helps prevent adulteration and substantiate claimed safety and potency. There are also numerous regulatory requirements that need to be met. Manufacturing activities are part of fulfilling the Chains of Compliance, i.e. chain of identity, chain of custody and chain of condition. Switching to the commercial side of this discussion, manufacturing has a direct impact on a company's profitability given its influence on the cost of goods as well as the cost of quality. But the commercial conversation does not end with manufacturing's influence on cost. Manufacturing decisions play a role in how therapies can be stored and distributed. Thereby playing a part in patient access, especially in rural and remote locations. Planning for manufacturing determines the capacity to produce and the capabilities of how to produce, supporting centralised production or decentralised production such as points of care manufacturing. The bottom line is manufacturing not only provides the necessary qualifications to operate but also determines the value of a biotechnology company.

When the opportunity arose, CCRM Australia conceptualised the Solutions for Manufacturing Advanced Regenerative Therapies CRC (SMARTCRC) to address multiple challenges that lay along the translation and commercialisation pathway (product, process and clinical development) through platform technologies. Innovative platform technologies created in Australia can help current and future efforts by building capabilities in manufacturing that benefit the biotechnology company as described above.

To cite an example, the Research Program on biomanufacturing focuses on developing new bioprocessing techniques, incorporating novel automation and scaling technologies into bioreactors, and investigating new assays that measure quality and potency. Successful outcomes will likely increase translation efficiency or faster time to market with regards to process development, lower cost of manufacture, ability to comply with stricter regulatory expectations, and potentially a modular platform that can better support decentralised manufacturing, even points of care manufacturing. No doubt there will be other benefits but it should be clear that manufacturing is more than just a production or a cost-related activity but a potential means to gain a competitive advantage in the marketplace.

The SMARTCRC program does not just stop at overcoming manufacturing challenges, it also aims to make an impact on the commercialisation process as well as contribute to the creation of a sustainable cell and gene therapy workforce, especially a workforce that overcomes the skills gap identified by the MTPConnect REDI Program. To assist in the commercialisation process, the SMARTCRC will have a comprehensive commercialisation strategy led by CCRM Australia, which is supported by an Australian & international partner network of professional services providers in areas of intellectual property protection, regulatory and market access, venture capital firms as well partners who provide access to facilities and logistics.

With 55 partners comprising regenerative therapy manufacturers, developers, suppliers, SMEs, government agencies and universities, the SMARTCRC is expected to produce novel platform technologies that overcome manufacturing-related challenges along the commercialisation pathway and at the same time create new capabilities that support the ambitious business model of the industry partners. To ensure that not only the industry partners benefit from the CRC's innovation but also future biotechnology companies seeking to commercialise their therapies, SMARTCRC will make the platform technologies accessible during the companies' research and development phases with eventual licensing agreements. Moreover, with advanced training and

upskilling of existing and future personnel to provide the business and technical skills to develop, manufacture and commercialise new regenerative therapy treatments, the legacy of the SMARTCRC will result in the rising tide that lifts all boats.

The NSW Stem Cell Network is a partner to CCRM Australia in the SMARTCRC and we are proud to continue our long-standing support of the NSW Stem Cell Network and congratulate the Network on this important publication. The Snapshot continues to serve as an invaluable tool for the industry. By fostering collaboration and innovation, we can ensure that Australia plays a leading role in the global regenerative medicine landscape.

Dr Chih Wei Teng

Vice President Corporate Development
CCRM Australia Ltd

.

For more information, please contact:

Deb Roosz

Manager, NSW Stem Cell Network

Phone: (02) 9552 9982

Email: stemcellmanager@stemcellnetwork.org.au

WAS THE DECLINE IN VENTURE FINANCING PARTIALLY FUELLED BY A BREAKDOWN IN THE TRIPLE HELIX INNOVATION MODEL?



Observing recent investment trends in the global cell therapy sector suggests that we have reached peak interest (Figure 1). However, such dramatic swings in biotechnology investments are not unusual. Recall the broken promise of gene therapies in the late 1990s and early 2000s, which resulted in much disappointment only to see us living through its revitalisation in 2023 and 2024. I accept that this does not alleviate the apprehension and challenges in capital raising faced by many cell therapy-based biotechnology companies.




Figure 1: Aggregate venture financings (Series A – Series D) for cell therapy companies by cell source

No doubt punters, academics and industry experts have hypothesised and given many reasons for the declining investment in cell therapies. I heard these repeated by several stakeholders I reached out to in preparation for this blog post. Some observations pointed to the November 2023 announcement from the FDA about its investigation into the risk of T cell malignancies. The FDA article prompted swift responses from academics and industry, including an article published in Nature Medicine, but investors were already spooked. As such, investors and prospective biopharmaceuticals looking for investment and licensing opportunities were not only more cautious, but also renewed their interest in exploring other treatment modalities. Other observations reflected concerns about high costs, unsustainable healthcare budgets and elusive strong revenues from approved cell therapies as described in the literature.

What initially sparked my curiosity were discussions with venture capitalists and biotechnology companies who raised concerns about the lack of government leadership in advancing novel therapeutics. Between the political squabbles in the United States and a wounded post-COVID China, which government can truly claim to focus on setting the right conditions for innovation? In those discussions, I started to think more about the role of government in incentivising and disincentivising

2024

innovation, especially during the COVID-19 pandemic. It is hard to overlook the steep rise in investments at the beginning of the COVID-19 pandemic, followed by the sharp decline after 2021.

The COVID-19 pandemic had some negative impacts on the innovation of medicines, and consequently investment dollars. The most obvious are the operational impacts, described in many publications, including the one by Qiu et al on disruptions to supply chains, clinical trials and market access. This severely impacted promising startups and projects at the preclinical and clinical development phases. The critical shortages of products, such as saline solution, prevented many experiments and production runs from taking place. In fact, the shortage of saline solution is still experienced in the second half of 2024. The COVID-19 black swan event put an end to countless investor-backed projects and, needless to say, resulted in financial losses.

However, there is a more subtle negative impact hidden in the shadows of the remarkable breakthrough of the mRNA vaccine that warrants more attention. While we can all celebrate the amazing speed and immense global collaboration undertaken for the vaccine's development, this modern miracle can be explained and enabled through the Triple Helix Model of Innovation. This model, which fosters interactions between academia, industry and government, creates the conditions necessary to fast-track the development and commercialisation of practical and marketable products and services. It was astonishing that the pandemic was declared during the first quarter of 2020, and by the end of the second quarter numerous candidates were lined up for clinical trials.

On one hand, we had the heroic success of the mRNA vaccine but something broke during the COVID-19 pandemic.

Fuelled by numerous pressures, governments decided that vaccination was the only way to address the COVID-19 pandemic. This approach was despite many biotechnology companies pivoting their investigational new drugs (INDs) or technologies to treat symptoms or effects of COVID-19. Publications such as those by Nobari et al outlined a list of clinical trials, some of which involved using cell-related therapies to treat the adverse effects of COVID-19.

No doubt investors would have jumped on the bandwagon to finance promising therapies to treat COVID-19 given the eminent global crisis and the willingness of the FDA to issue Emergency Use Authorizations. It was potentially a quick return on investment. Research by Yu et al concluded that many COVID-19 solutions were privately funded. But it was all hands on deck with the vaccine program. Government funding was channelled to accelerate vaccine research, such as the United States' Operation Warp Speed, clinical trials refocused to support promising vaccine candidates from Big Pharma, health policies in major jurisdictions shifted from curative to preventative measures, and budgets were shored up in anticipation of purchasing large quantities of approved vaccines.

The pressure to develop and promote a vaccine solution was so great that regulators discouraged the use of non-approved medication to treat COVID-19. Physicians who sought to repurpose medications for off-label use were at risk of losing their licenses. The fast-paced, multifaceted, multi-modal efforts to challenge the COVID-19 pandemic were suddenly reduced to one. I doubt the investors who backed any COVID-19-related medical devices or cell and gene therapy companies (other than Pharma with approved vaccines) ever saw their return.

Circling back to the Blog Carnival's topic, will we see a permanent decline in cell therapy investments? I think otherwise.

Yes, we were getting a reality check on our over-enthusiastic foray into CAR-T but what hit the industry hard was the black swan event that is COVID-19 and the irrational decision of governments to dictate silver bullets to solve problems. Luckily for us, black swan events are rare. One can only hope governments limit their intervention and take better counsel from the different teams of physicians and allied health professionals operating at the coalface.

I'm optimistic that, in time, innovative cell therapies that were born out of the COVID-19 pandemic will eventually receive market authorisation to treat respiratory diseases, inflammation issues, heart failure and other medical conditions.

The truly undesirable outcomes are these: the prolonged drought caused by unrealised cell therapies, CAR-T therapy and an inability to recoup via COVID-19 investments meant that investors' war chests were either running dry or the purse strings tightened, and governments have less money to spend now than before the COVID-19 pandemic. Biotechnology companies need to do things more efficiently and work smarter to get breakthrough results. Maybe going back to fundamentals on developing a breakthrough therapy and manufacturability are not necessarily bad things because investors' appetites will return. After all, this decline was not due to the failure of cell therapy as a treatment modality, but a series of unfortunate events.

My blog is just one of many covering this topic as part of Signal's eighth annual blog carnival. Please click [Signals](#) to read what other bloggers think about the topic.

Dr Chih Wei Teng

Vice President Corporate Development
CCRM Australia Ltd

References

1 Bak P et al. (2023) Investment and Development Landscape of Autologous and Allogenic Cell Therapies. (<https://www.bbbsa.com/featured-news-home/2023/8/19/celltherapies>)

2 FDA (2023). FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. (<https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous>)

3 Ghilardi G et al (2024). T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nature Medicine.

4 Joshua J (2024). Science Continues To Outpace Commercialization Of Cell And Gene Therapies. (<https://www.forbes.com/sites/joshuacohen/2024/03/04/science-continues-to-outpace-commercialization-of-cell-and-gene-therapies/>).

5 Kelkar A et al (2023). CAR T not cost-effective as second-line therapy for diffuse large B-cell lymphoma at current prices, study finds. Annals of Internal Medicine.

- 6 Trusheim M (2023). Value creators or financial destroyers? The potential of gene therapies to transform healthcare. (<https://www.statnews.com/sponsor/2023/11/15/value-creators-or-financial-destroyers-the-potential-of-gene-therapies-to-transform-healthcare/>)
- 7 Qiu et al (2021). The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects. Drug Discov Today.
- 8 Landau S & Lim J (2024). Global shortage of saline solution affecting Australian healthcare system. ABC News (<https://www.abc.net.au/news/2024-07-25/shortage-saline-impact-australia-healthcare/104143020>).
- 9 Nobari S et al (2022). Cellular Therapy: The Hope for Covid-19. Avicenna J Med Biotechnol.
- 10 Yu et al (2023). Biopharma innovation trends during COVID-19 and beyond: an evidence from global partnerships and fundraising activities, 2011-2022. Global Health.
- 11 Reliefweb (2021). Pfizer, BioNTech and Moderna making \$1,000 profit every second while world's poorest countries remain largely unvaccinated. (<https://reliefweb.int/report/world/pfizer-biontech-and-moderna-making-1000-profit-every-second-while-world-s-poorest>)



AUSTRALIAN-BASED COMPANIES

Cynata Therapeutics Ltd is a clinical stage biotechnology company developing a proprietary therapeutic platform technology, known as Cymerus™. The platform is based on discoveries made at the University of Wisconsin-Madison, a world leader in stem cell research. Cymerus addresses a critical shortcoming in existing methods of production of allogeneic mesenchymal stem cells (MSCs) for therapeutic use: the ability to achieve consistent economic manufacture at commercial scale without reliance upon multiple donors. There is extensive interest in the development of MSCs as therapeutic agents, in light of their ability to secrete bioactive molecules such as cytokines, chemokines, and growth factors, in addition to their immunosuppressive and immunoregulatory properties. There are currently over 1000 clinical trials of MSCs, covering an extremely wide range of therapeutic indications, including haematological, cardiovascular, orthopaedic, gastrointestinal, and autoimmune disorders, among others. However, there are very major limitations in conventional methods of MSC production including the dependence upon multiple donors, the variability between donors, the relative scarcity of MSCs in adult tissue, and the low proliferative capacity of adult stem cells compared to pluripotent stem cells. Cynata believes that the Cymerus technology addresses these issues, uniquely placing Cynata to capitalise on the flourishing field of stem cell therapeutics. The Company has been covered in highly favourable equity research analyses published by Baillieu Holst, BBY, SeeThru Equity, H.C. Wainwright, Shaw & Partners, and MST Access. Cynata's first therapeutic product CYP-001 has shown highly promising efficacy in a Phase 1 clinical trial in acute graft-versus-host disease (aGvHD). This has enabled the Company to initiate multiple further clinical trials. Cynata has a strategic partnership with FUJIFILM, a major participant in the regenerative medicine sector and the third largest shareholder in Cynata, behind Fidelity and BioScience Managers, with around 6% of the shares.

PRODUCT PIPELINE

Cynata is the world leader in developing iPSC-derived cell therapy products. Following excellent results in a Phase 1 clinical study in a GvHD, the Company filed an IND application with the US FDA and secured clearance of that IND in 2022, enabling trial start-up activities to commence on a potential Phase 2 clinical trial in aGvHD. A phase 3 clinical trial commenced in 2020 in osteoarthritis in association with the University of Sydney while a clinical trial in diabetic foot ulcers commenced in 2021. A clinical trial in patients with severe respiratory complications, such as have been seen in COVID-19, patients, commenced in 2020. However this trial concluded in 2022 due to ongoing recruitment challenges. The Phase 1 clinical trial results in aGvHD, which have been the subject of a front-page article in Nature Medicine, provide a sound foundation for further development in numerous other indications, such as those in which MSCs from other sources have previously been investigated. Cynata has also reported clear efficacy in pre-clinical proof-of-concept studies with its Cymerus MSC products in models of cytokine release syndrome (CRS), CLI, diabetic wounds, myocardial infarction, asthma, idiopathic pulmonary fibrosis, sepsis, acute respiratory distress syndrome (ARDS) and in GvHD. Cynata is pursuing a vigorous partnering agenda in order to fully exploit its outstanding cell therapy platform.

LATEST NEWS

Active recruitment has continued in the osteoarthritis and diabetic foot ulcer trials. The long-standing relationship with FUJIFILM was strengthened with the establishment of a new strategic partnership involving manufacturing services to ensure long term supply of Cynata's proprietary Cymerus MSC products. Cynata has successfully achieved IND clearance from the US FDA for a proposed Phase 2 clinical trial in aGvHD. Additionally, the Company's intellectual property portfolio has advanced with the grant of patents in multiple jurisdictions, including the USA.



CEO: Dr Kilian Kelly

Established in Australia in 2011

ABN: 98 104 037 372

Status: PUBLIC (ASX:CYP)

www.cynata.com


CONTACT

Dr Kilian Kelly

E: kilian.kelly@cynata.com

cynata

therapeutics





Specialists in ultra-low temperature storage and cryogenic storage

Biological storage specialists

Cryosite specialises in biobanking services. We provide long term secure storage across various temperature ranges for human cells, pharmacokinetic (PK) samples and material for GMP.

We also store investigational products and scheduled drugs.

Our wide range of services include:

- 24 hour temperature monitoring
- Independent backup power by two generators
- Secure IT systems with offsite backups
- Validated inventory management system
- Validated quality management system

- **ADVANCED THERAPIES (ATMPs)**
- **CELL BANKS (MCB, WCB, STEM CELLS)**
- **CRYOGENIC STORAGE & TRANSPORT**
- **BLOOD SAMPLES**
- **RESEARCH SAMPLES**



Blast Freezer

+40°C
-20°C



Ambient

15°C - 25°C



Cold

2°C - 8°C



Vault

15°C - 25°C
2°C - 8°C



Frozen

-20°C
-40°C
-80°C



Liquid Nitrogen

-196°C

Partnered with



cryosite
biological storage specialists

+61 2 8865 2000 biologicals@cryosite.com www.cryosite.com

Licenses held include: TGA License Number MI-18072008-LI-002488-11 • Class 5.11 Biosecurity Containment – N2115 • NSW Health Department Licence (GWP)



Mesoblast is using its proprietary technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases resistant to conventional standard of care and where inflammation plays a central role.

The Company's portfolio of Phase 3 product candidates comprises RYONCIL® (remestemcel-L) for steroid-refractory acute graft versus host disease (SR-aGvHD) and biologic-resistant inflammatory bowel disease, REVASCOR® (rexlemestrocil-L) for advanced chronic heart failure in adults and for hypoplastic left heart syndrome (HLHS) – a pediatric congenital heart disease, and MPC-06-ID (rexlemestrocil-L) for chronic low back pain due to degenerative disc disease. Mesoblast also has a promising emerging pipeline of product candidates and next generation technologies.

Innovative technology platform enables scalable manufacturing

Mesoblast's novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.

Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes. Another key feature of Mesoblast's cells is they can be administered to patients without the need for donor–recipient matching or recipient immune suppression.

Mesoblast has proprietary technology that facilitates the increase in yields necessary for the long-term commercial supply of its product candidates, and next generation manufacturing processes using xeno-free technologies and three-dimensional bioreactors to reduce labour, drive down cost of goods and improve manufacturing efficiencies.

Robust Intellectual Property Estate

Mesoblast has an extensive patent portfolio with over 1,100 patents and patent applications across 82 patent families, and patent terms extending through 2040. These patents cover composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells, and provide strong commercial protection for our products in all major markets, including the United States, Europe, Japan and China. Licensing agreements with JCR, Grünenthal, Tasy and Takeda highlight the strength of Mesoblast's extensive intellectual property portfolio covering mesenchymal lineage cells.

Mesoblast will continue to use its patents to prosecute its commercial rights as they relate to its core strategic product portfolio. When consistent with the Company's strategic objectives, it may consider providing third parties with commercial access to its patent portfolio.

Evidence-based Science and Translational Medicine

Mesoblast's approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. These safeguards are intended to ensure the integrity and reproducibility of results, and to ensure that outcomes observed are scientifically reliable.

Global Operations

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).



Chief Executive: Dr. Silviu Itescu

Established in Australia 2004

ABN: 68 109 431 870

Status: Public

www.mesoblast.com

info@mesoblast.com



Mesoblast Limited is a global leader in cellular medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates.



CLINICAL TRIALS IN AUSTRALIA

CLINICAL TRIALS

In September 2021, the Regenerative Medicines Catalyst Programme released an up-to-date and extensive overview of Australia's Regenerative Medicine Clinical Trials Database, which can be viewed [here](#). Read more about the report [here](#).



COMPANY DIRECTORY

DIRECTORY

COMPANIES DEVELOPING ADVANCED MEDICINES

Company	Website	Location
Algorae Pharmaceuticals (formerly Living Cell Technologies)	algoraepharma.com	VIC
BioOra	bioora.com	NZ
Cancure	cancure.com	QLD
Carina Biotech	carinabiotech.com	SA
Cartherics	cartherics.com	VIC
Celosia Therapeutics	celosiatx.com	NSW
CSL	csl.com.au	VIC
Currus Biologics	currusbio.com	VIC
Cynata	cynata.com	VIC
HaemaLogiX Pty Ltd	haemalogix.com	NSW
Imugene Ltd	imugene.com	NSW
Mesoblast	mesoblast.com	VIC
Orthocell	orthocell.com	WA
Prescient Therapeutics	ptxtherapeutics.com	VIC
PYC Therapeutics	pyctx.com	WA
Skin2Neuron	skin2neuron.org	NSW
Tessara Therapeutics	tessaratherapeutics.com	VIC

DIRECTORY

TGA LICENSED GMP FACILITIES (AND PROCESS DEVELOPMENT)

Company	Website	Location
Biocina	biocina.com	SA
Biovirus (NZ - not TGA)	biovirus.com	NZ
Cell & Tissue Therapies Western Australia (CTTWA)	rph.health.wa.gov.au/Services/Cell-and-Tissue-Therapies-WA	WA
Cell Therapies Pty Ltd	celltherapies.com.au	VIC
CSL Ltd	csl.com	VIC
Orthocell	orthocell.com	WA
Pantheon by Thermo Fisher	thermofisher.com/au/en/home/brands/patheon.html	QLD
Q-Gen Cell Therapies	qimrberghofer.edu.au/commercial-collaborations/partner-with-us/q-gen-cell-therapeutics	QLD
Royal Brisbane and Women's	metronorth.health.qld.gov.au/rbwh	QLD
Scinogy	scinogy.com	VIC
Sydney Cell and Gene Therapy	sydneycellandgenetherapy.org	NSW

PROCESS DEVELOPMENT-ONLY FACILITIES

Company	Website	Location
Centre for Advanced Therapies (CAT) at Royal Perth Hospital	rph.health.wa.gov.au/Services/Cell-and-Tissue-Therapies-WA	WA
Centre of Excellence in Cellular Immunotherapies, Peter Mac	petermac.org/research/research-centres-and-centres-of-excellence/centre-of-excellence-in-cellular-immunotherapy/about-the-centre-excellence-in-cellular-immunotherapy	VIC
University of Queensland/CCRM Australia	ccrmaustralia.com.au/news/advanced-cell-therapy-manufacturing-initiative-to-be-established-in-brisbane	QLD

DIRECTORY

NON TGA LICENSED PHASE 0/1 MANUFACTURE FACILITIES

Company	Website	Location
Cell & Molecular Therapies, Royal Prince Alfred Hospital	slhd.health.nsw.gov.au/rpa-hospital-research/cell-molecular-therapies	NSW
Hudson Cell Therapies	hudson.org.au/facilities/hudson-cell-therapies/	VIC
Magellan Stem Cells	magellanstemcells.com.au	VIC
Westmead Viral Vector Manufacturing Facility, Stage 2, Westmead Health Precinct	westmeadhealthprecinct.com	NSW

ADVANCED MEDICINE TOOLS PROVIDERS

Company	Website	Location
Biomerieux	biomerieux.com	NSW
Biorad	bio-rad.com	NSW
Celleo	celleo.com	VIC
Charles River Laboratories	.criver.com/microbial-solutions-facility-melbourne-australia	VIC
Culturon	culturon.com.au	NSW
Cytiva	cytivalifesciences.com	NSW
Decode Science Pty Ltd	decodescience.com.au	VIC
Eppendorf	eppendorf.com	NSW
GenScript	genscript.com	N/A
In Vitro Technologies	invitro.com.au	NSW
Inventia Life Science	inventia.life	NSW
Invetech	invetechgroup.com	VIC
Lonza	lonzaboiscience.com.au	NSW
Merck Group	sigmaaldrich.com	NSW
Messenger Bio	messenger.bio	VIC
Miltenyi Biotec	miltenyi.com	NSW
Sartorius	sartorius.com/en	VIC
Scientifix Pty. Ltd.	scientifix.com.au	VIC
Scinogy	scinogy.com	VIC
Stemcell Technologies	stemcell.com	VIC
Terumo BCT	terumobct.com	NSW
Thermofisher	thermofisher.com.au	NSW

DIRECTORY

ADVANCED MEDICINE CRO/CSO

Company	Website	Location
CryoPDP	cryopdp.com	NSW
Eurofins	eurofins.com.au	NSW
IQVIA	iqvia.com	NSW
Phenomics Australia	phenomicsaustralia.org.au	ACT
World Courier AmerisourceBergen	worldcourier.com	NSW

ADVANCED MEDICINE CONSULTING SERVICES

Company	Website	Location
Alithia Life Sciences	alithialifesciences.com	VIC
Asia Pacific Consultants Pty. Ltd.	a-p-c.com.au/services/gmp-and-quality-systems	NSW
Biointelect Pty Ltd	biointelect.com	NSW
Centre for Biopharmaceutical Excellence	cbe-ap.com.au	VIC
Increment4 Pty. Ltd.	increment4.com	VIC
ProPharma Group	propharmagroup.com	VIC

COMMERCIAL PROVIDERS OF ADVANCED MEDICINES

Company	Website	Location
Gilead Science	gilead.com.au	NSW
Janssen-Cilag	janssen.com/australia	NSW
Novartis Pharmaceuticals Australia Pty Ltd	novartis.com/au-en	NSW
Orthocell	orthocell.com	WA

DIRECTORY

INSTITUTIONS TREATING PATIENTS WITH CGT PHARMACEUTICALS

Company	Website	Location
Alfred Health Victoria	alfredhealth.org.au	VIC
Australasian Leukaemia and Lymphoma Group	allg.org.au	VIC
Chris O'Brian Lifehouse	mylifehouse.org.au	NSW
Fiona Stanley Hospital	fsfhg.health.wa.gov.au	WA
Monash Health	monashhealth.org	VIC
Murdoch Children's Research Institute	mcri.edu.au	VIC
Peter MacCallum Cancer Centre	petermac.org	VIC
QIMR Berghofer Medical Research Institute	qimrberghofer.edu.au	QLD
Royal Perth Hospital	rph.health.wa.gov.au	WA
Sir Charles Gairdner Hospital	scgh.health.wa.gov.au	WA
St. Vincent's Hospital Sydney	svhs.org.au	NSW
Western Sydney Local Health District	wslhd.health.nsw.gov.au	NSW
Westmead Hospital/Western Sydney LHD	wslhd.health.nsw.gov.au/Westmead-Hospital	NSW

NON TGA AUTOLOGOUS MESENCHYMAL TRANSPLANT

Company	Website	Location
Magellan	magellanstemcells.com.au	VIC
Cell Innovations	cell-innovations.com.au	NSW

DIRECTORY

CLINICAL TRIALS OF ADVANCED MEDICINES

Company	Website	Location
Bayer	bayer.com.au/en	N/A
Biogen Inc	biogen.com	N/A
BioMarin Pharmaceutical Inc.	biomarin.com	NSW
Bristol Myers Squibb Australia	bms.com/au	VIC
Cynata Therapeutics Ltd	cynata.com	VIC
GlaxoSmithKline	gsk.com/en-gb	NSW
Pfizer	pfizer.com.au	NSW
Roche	roche-australia.com	NSW

FUNDING SOURCES

Company	Website	Location
Bioscience Managers Pty Ltd	biosciencemanagers.com	VIC
Brandon Capital Partners Pty Ltd	brandoncapital.vc	NSW/VIC
IP Group Pty Ltd	ipgroupanz.com	NSW
Morgans Pty Ltd	morgans.com.au	QLD
Medical Research Future Fund	health.gov.au/our-work/medical-research-future-fund	N/A
OneVentures Pty Ltd	one-ventures.com.au	NSW

DIRECTORY

RESEARCH FACILITIES

Company	Website	Location
Australian Regenerative Medicine Institute	armi.org.au	VIC
Bond University	bond.edu.au	QLD
Charles Darwin University	cdu.edu.au	NT
Children's Medical Research Institute	cmrijeansforgenes.org.au	NSW
Curtin University	curtin.edu.au	WA
Edith Cowan University	ecu.edu.auresearch	WA
Flinders University	flinders.edu.au	SA
Florey Institute of Neuroscience	florey.edu.au	VIC
Garvan Institute of Medical Research	garvan.org.au	NSW
Harry Perkins Research Institute	perkins.org.au	WA
James Cook University	jcu.edu.au	QLD
Lions Eye Institute	lei.org.au	WA
Macquarie University	mq.edu.au	NSW
Monash University	monash.edu	VIC
Murdoch Children's Research Institute (MCRI)	mcri.edu.au	VIC
Murdoch University	murdoch.edu.au	WA
QIMR Berghofer Medical Research Institute, Q-Gen Cell Therapeutics	qimrberghofer.edu.aucommercial-collaborations/partner-with-us/q-gen-cell-therapeutics	QLD
Queensland Immunology Research Centre	qirc.com.au	QLD
Queensland University of Technology	qut.edu.au	QLD
ReNEW at MCRI	mcri-renew.org.auabout	VIC
Telethon Kids Institute	telethonkids.org.au	WA
Translational Research Facility of the Monash Health Translation Precinct	mhtp.org.au	VIC
University of Adelaide	adelaide.edu.au	SA
University of Melbourne	unimelb.edu.au	VIC
University of NSW	unsw.edu.au	NSW
University of Queensland	uq.edu.au	QLD
University of South Australia	unisa.edu.au	SA
University of Sydney	sydney.edu.au	NSW
University of Tasmania	utas.edu.au	TAS
University of Technology Sydney	uts.edu.au	NSW
University of Western Australia	uwa.edu.au	WA
University of Wollongong	uow.edu.au	NSW

DIRECTORY

OTHER RM PRODUCT DEVELOPERS

Company	Website	Location
Anteris Technologies	anteristech.com/home.html	WA
Anatomics Pty Ltd	anatomics.com	VIC
Avita Medical	avitamedical.com	VIC
Osteopore	osteopore.com	WA
Polynovo Ltd	au.polynovo.com	VIC
ReNerve	renerve.com.au	VIC
Vivazome	vivazome.com	VIC

CELL AND TISSUE REPOSITORIES

Company	Website	Location
BDMI Cord Blood Bank	parentsguidecordblood.org/en/banks/bmdi-cord-blood-bank	VIC/NSW/QLD
Cell Care	cellcare.com.au	VIC
Cryosite Ltd	cryosite.com	VIC
NSW Statewide Biobank	biobank.health.nsw.gov.au	NSW
Sydney Cord Blood Bank	schn.health.nsw.gov.au/find-a-service/health-medical-services/sydney-cord-blood-bank	NSW

DIRECTORY

SUPPORTING INITIATIVES

Company	Website	Location
ARCS Australia Ltd.	arcs.com.au	NSW
Australasian Society for Stem Cell Research	asscr.org	N/A
Australasian Gene and Cell Therapy Society	agcts.org.au	N/A
Australian Red Cross Lifeblood	lifeblood.com.au	NSW
Australia's Industry Growth Centre	industry.gov.au/science-technology-and-innovation/industry-innovation/industry-growth-centres	ACT
BioCurate	biocurate.com	VIC
Centre for Commercialisation of Regenerative Medicine Australia	ccrmaustralia.com.au	VIC
Cell and Gene Therapy Catalyst	ausbiotech.org/programs/australias-cell-and-gene-catalyst	N/A
Cerebral Palsy Alliance	cerebralpalsy.org.au	NSW
CSIRO	csiro.au/en	ACT / NSW
Foundation for the Accreditation of Cellular Therapies	factglobal.org	N/A
International Society for Cell Therapy Australia and New Zealand (ANZ)	isctglobal.org/about/about-us	N/A
Jumar Biocubator	jumarbio.com	VIC
Medicines Australia	medicinesaustralia.com.au	ACT
MTP Connect/ REDI	mtpconnect.org.au/programs/REDI	N/A
NSW Stem Cell Network	stemcellnetwork.org.au	NSW
Therapeutic Innovations Australia	therapeuticinnovation.com.au	Australia

